The Board granted increased ratings for dermatitis and central serous chorioretinopathy, while denying restoration of the rating for prostate cancer and granting SMC for loss of a creative organ.
The deciding factor: The decision was based on the evidence showing that the Veteran's dermatitis required constant or near-constant systemic therapy, supporting an increased rating. The reduction in the prostate cancer rating was proper due to remission and cessation of therapeutic procedures, while service connection for central serous chorioretinopathy was granted as a secondary condition.
- Claimed conditions
- Dermatitis associated with TERA participation, Prostate cancer, Central serous chorioretinopathy (secondary to dermatitis), Loss of use of a creative organ
- How they argued it
- Secondary to another service-connected condition
- Exposure basis
- None
- Rating assigned
- 60%
- Decision date
- November 7, 2025
- Citation
- A25097055
Want to see how appeals like this one tend to go? Appeals like mine
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.